期刊文献+

国产固定剂量复合剂治疗肺结核的临床近期效果观察 被引量:4

Controlled Clinical Study on Efficacy of National Fixed-Dose Compounds in Antituberculosis Chemotherapy
下载PDF
导出
摘要 目的全面评价国产固定剂量复合剂异烟肼利福平吡嗪酰胺/异烟肼利福平(2HRZ/4HR)的抗结核疗效及毒副反应。方法将81例初治菌阳肺结核患者,随机分为治疗组(2HRZ/4HR)和对照组(2HRZ/4HR)观察近期痰菌阴转率、X线病灶改变及不良反应。结果治疗组和对照组2个月痰菌阴转率分别达82.5%和65.7%;满疗程痰菌阴转率各为100.0%和88.6%;胸部X线明显改善,治疗组和对照组病灶吸收分别占92.7%和94.3%,两组空洞闭合率分别为63.2%和62.5%;治疗组和对照组各有2例和4例肝功异常。结论国产固定复合剂是一种安全、高效、易被患者接受、具有推广应用前景的抗结核药物。 Objective To evaluate the treatment outcome and side-effects of national fixed-dese compounds(2HRZ/4HR). Methods 81 new bacteriological positive pulmonary tuberculosis patients were divided randomly into treatment group(42 cases)and control( 39 cases) group. Results The sputum negative conversion rates at the 2nd month in 山e treatment and the controlgroup were 82.5% and 65.7% respectively. And the rates at the end of the chemotherapy were 100.0% and 88.6% respectively. Chest radiography showed remarkable improvement. The resolution of puhnonary lesions in the treatment group and the control group accounted for 92.7% and 94. 3% respectively,The Cavity closure rates were 63.2% in the treatment group and 62.5% in the control group. Two patients defaulted because of hepatic dysfunction in the treatment group and 4 patients in the control's. Conclusion National fixed-dose compounds rifater/rifinah show excellent therapeutic efflcacy,safety and compliance in antituberculous chemotherapy,which could be recommended for wider use in tuberculosis control in China.
出处 《临床肺科杂志》 2008年第7期824-825,共2页 Journal of Clinical Pulmonary Medicine
关键词 固定剂量复合剂 肺结核 临床分析 治疗方法 Fixed-dose cmnpounds Pulmonary tuberculosis/drog therapy
  • 相关文献

参考文献7

  • 1中华人民共和国卫生部.2000年第四次全国肺结核病流行病学抽样调查[M].北京:人民卫生出版社,2003.15-26.
  • 2Internationnal Union against Tuberculosis and Lung Disease. Anfituberculosis regl mens of the chemotherapy. Recommendations from the committee on treatment of the Internationnal Union against Tuberculosis and Lung Disease. Bull Int Union Tlberc Lung Dis,1998,63:60 -64.
  • 3World Health Organization Tuberculosis rogram. Treatment of tuberculosis : guidelines for national programmes. Geneva: WHO, 1993.
  • 4Fox W. Drug combinations and the bioavailability of rifampicin. Tubercle, 1990,71:241 -245.
  • 5Botha FJ, Sirgel FA, Parkixl DP, et al. Eally bactericidal actiVity of ethambutol, pyrazinamide and the nxed combination of isoniazid, rifampicin and pyrazinamide(Rifater) in patients with pulmonary tuberculosis. S Afr Med J,1996,86:155 -158.
  • 6赵伟杰,李惠文,段连山,梁桂芳,张彤群,陆宇.国产抗结核固定剂量复合剂的药效学和药代动力学研究[J].中华结核和呼吸杂志,2002,25(6):333-336. 被引量:26
  • 7严晓峰,曹培明.费宁、费安与HRZ治疗肺结核的临床疗效对比[J].临床肺科杂志,2006,11(2):161-161. 被引量:3

二级参考文献4

  • 1中华医学会结核病学分会.中国结核病分类法[J].中华结核和呼吸杂志,1998,21(12):716-716.
  • 2World Health Organization.Bulletin of the World Health Organization,2001,79:61~68.
  • 3C. Lacroix,T. Phan Hoang,J. Nouveau,C. Guyonnaud,G. Laine,H. Duwoos,O. Lafont. Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects[J] 1989,European Journal of Clinical Pharmacology(4):395~400
  • 4赵伟杰,李惠文,段连山,梁桂芳,张彤群,陆宇.国产抗结核固定剂量复合剂的药效学和药代动力学研究[J].中华结核和呼吸杂志,2002,25(6):333-336. 被引量:26

共引文献28

同被引文献32

引证文献4

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部